ClinicalTrials.gg
CompletedNCT03766724Updated Apr 10, 2019

Pharmacokinetic and Pharmacodynamic Drug-Drug Interaction of Evogliptin and Empagliflozin or Dapagliflozin in Healthy Male Adults

A Phase 1 interventional study of Evogliptin→Evogliptin+Empagliflozin→Empagliflozin and Empagliflozin→Evogliptin→Evogliptin+Empagliflozin in Type2 Diabetes, sponsored by Dong-A ST Co., Ltd.. Completed at 1 site in Korea, Republic of. Open to male participants aged 19 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-04-10.

Sponsored by Dong-A ST Co., Ltd. · Phase 1, Interventional, and Health services research

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
42
Allocation
Randomized
Ages
19 Years to 55 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 130 studies testing empagliflozin in Diabetes Mellitus, Type 2 — 18 open to participants now, 19 under way, 1 of them phase 3. empagliflozin · Diabetes Mellitus, Type 2.

Enrollment
89th of 130
42 · median 79
Started
2018
with 7 others
Phase 1
24 of 130
5 open now
Registered
68th of 130
by date

Among the 130 studies testing empagliflozin in Diabetes Mellitus, Type 2, this one is the 89th largest by enrollment, is one of 8 that started in 2018, is one of 24 in phase 1, and was the 68th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

18 of the 130 studies testing empagliflozin in Diabetes Mellitus, Type 2 are open now, in 10 countries. Recruiting first, the newest first:

13 more — sign in →

By country, each count listing its studies:

All 18 open studies →

About empagliflozin

empagliflozin: first FDA approval 2014 (JARDIANCE), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 19 Years to 55 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 130 studies testing empagliflozin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

A Randomized, Open-label, Multiple-dose, Crossover Study to Investigate the Pharmacokinetic and Pharmacodynamic Drug-Drug Interaction of Evogliptin 5 mg and Empagliflozin 25 mg or Dapagliflozin 10 mg after Oral Administration in Healthy Male Adults

03

Conditions studied

  • Type2 Diabetes
04

Who can participate

Ages eligible
19 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Health Male Volunteers (Age : 19\~55 years)
  • Body Weight≥55kg, 18.5≤\<25.0

Exclusion criteria

Exclusion Criteria:

  • galactose intolerance, Lapp lactase deficiency, glucose-galactose malabsorption
  • Allergy or Drug
  • Medical History
  • , ALT > Upper Normal Range*1.25, \<60mL/min/1.73㎡
  • Drink during clinical trial period
  • Smoking during clinical trial period
  • Grapefruit/Caffeine intake during clinical trial period
  • No
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
42 participants (actual)

Study arms

  • Experimental
    Group A

    Evogliptin→Evogliptin+Empagliflozin→Empagliflozin

    Drug: Evogliptin→Evogliptin+Empagliflozin→Empagliflozin

  • Experimental
    Group B

    Empagliflozin→Evogliptin→Evogliptin+Empagliflozin

    Drug: Empagliflozin→Evogliptin→Evogliptin+Empagliflozin

  • Experimental
    Group C

    Evogliptin→Evogliptin+Dapagliflozin→Dapagliflozin

    Drug: Evogliptin→Evogliptin+Dapagliflozin→Dapagliflozin

  • Experimental
    Group D

    Dapagliflozin→Evogliptin→Evogliptin+Dapagliflozin

    Drug: Dapagliflozin→Evogliptin→Evogliptin+Dapagliflozin

Interventions

  • DrugEvogliptin→Evogliptin+Empagliflozin→Empagliflozin

    Drug page: Empagliflozin

    Evogliptin : Evogliptin 5mg QD, Evogliptin+Empagliflozin : Evogliptin 5mg QD + Empagliflozin 25mg QD, Empagliflozin : Empagliflozin 25mg QD

    Also known as: Suganon, Jardiance

  • DrugEmpagliflozin→Evogliptin→Evogliptin+Empagliflozin

    Drug page: Empagliflozin

    Empagliflozin : Empagliflozin 25mg QD, Evogliptin : Evogliptin 5mg QD, Evogliptin+Empagliflozin : Evogliptin 5mg QD + Empagliflozin 25mg QD

    Also known as: Suganon, Jardiance

  • DrugEvogliptin→Evogliptin+Dapagliflozin→Dapagliflozin

    Drug page: Dapagliflozin

    Evogliptin : Evogliptin 5mg QD, Evogliptin+Dapagliflozin : Evogliptin 5mg QD + Dapagliflozin 10mg QD, Dapagliflozin : Dapagliflozin 10mg QD

    Also known as: Suganon, Forxiga

  • DrugDapagliflozin→Evogliptin→Evogliptin+Dapagliflozin

    Drug page: Dapagliflozin

    Dapagliflozin : Dapagliflozin 10mg QD, Evogliptin : Evogliptin 5mg QD, Evogliptin+Dapagliflozin : Evogliptin 5mg QD + Dapagliflozin 10mg QD

    Also known as: Suganon, Forxiga

06

What researchers measure

Primary outcomes

  1. AUCτ,ss

    area under the concentration-time curve

    Time frame: 4 weeks

  2. Cmax,ss

    maximum serum concentration

    Time frame: 4 weeks

07

Study locations

1 site
  • Clinical Trials Center, Severance Hospital
    Seoul, 03722, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2018 to primary completion in Jan 2019, 1 month.

Of 453 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 11. This study's 1 month is below that.

Counting every sponsor, half of 515 studies reached it within 6 months; a quarter within 2 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 5, 2018
First posted
Dec 6, 2018
StartActual
Nov 22, 2018
Primary completionActual
Jan 18, 2019
CompletionActual
Jan 18, 2019
Last update
Apr 10, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 10, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03766724
Responsible party
Sponsor
First posted
Dec 6, 2018
Start date
Nov 22, 2018
Primary completion
Jan 18, 2019
Completion
Jan 18, 2019
Last update
Apr 10, 2019

Study contacts

Min soo Park, M.D., Ph.D.
principal investigator · Clinical Trial Center, Severance Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Empagliflozin · Dapagliflozin

Start the discussion